Molecular and immune biomarker testing in squamous-cell lung cancer: effect of current and future therapies and technologies.
AffiliationDivision of Medical Oncology, University of Colorado Cancer Center, Aurora, CO.
MetadataShow full item record
AbstractPatients with non-small-cell lung cancer, including squamous-cell lung cancer (SqCLC), typically present at an advanced stage. The current treatment landscape, which includes chemotherapy, radiotherapy, surgery, immunotherapy, and targeted agents, is rapidly evolving, including for patients with SqCLC. Prompt molecular and immune biomarker testing can serve to guide optimal treatment choices, and immune biomarker testing is becoming more important for this patient population. In this review we provide an overview of current and emerging practices and technologies for molecular and immune biomarker testing in advanced non-small-cell lung cancer, with a focus on SqCLC.
CitationMolecular and immune biomarker testing in squamous-cell lung cancer: effect of current and future therapies and technologies. 2018, 19(4): 331-339 Clin Lung Cancer
JournalClinical Lung Cancer
- Emerging drugs for squamous cell lung cancer.
- Authors: Cheng H, Shcherba M, Kandavelou K, Liang Y, Liu H, Perez-Soler R
- Issue date: 2015 Mar
- [Progress on the Study of Targeting FGFR in Squamous Non-small Cell Lung Cancer].
- Authors: Dong M, Li T, Chen J
- Issue date: 2018 Feb 20
- [Research status on molecular targeted therapy for squamous-cell lung cancer].
- Authors: Li Y, Zhou Y, Wang H
- Issue date: 2014 Aug 20
- [PD-L1 expression: An emerging biomarker in non-small cell lung cancer].
- Authors: Adam J, Planchard D, Marabelle A, Soria JC, Scoazec JY, Lantuéjoul S
- Issue date: 2016 Jan
- [Treatment of Advanced Squamous Cell Lung Cancer].
- Authors: Zhu Y, Xing P, Li J
- Issue date: 2016 Oct 20